Results 61 to 70 of about 23,130 (165)

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naïve Patients. [PDF]

Circulation
Vega RB, O'Mahony G, Barbour AM, Yu H, Knöchel J, Brengdahl J, Hochdörfer T, Bergenholm L, Töppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Lindén D, Rosenmeier JB.   +28 more
europepmc   +1 more source

Anifrolumab Plus Standard of Care Reduces Long-Term Cardiovascular Damage in Adults With Systemic Lupus Erythematosus: Findings From a Real-World External Control Study. [PDF]

ACR Open Rheumatol
Touma Z, Bruce IN, Furie RA, Morand EF, Tummala R, Chandran S, Abreu G, Knagenhjelm J, Emmas C, Agustin L, Richards C, Mehdikhanova T, Yang Z, Waratani M.   +13 more
europepmc   +1 more source

Characteristics and Outcomes of People With COPD Who Experience Exacerbations While on Inhaled Triple Therapy: Results of the SIRIUS I Cohort Study in the US (2015–2019)

International Journal of COPD
Clementine Nordon,1 Donna Carstens,2 Malin Fagerås,3 Hana Müllerová,1 Phani S Veeranki,4 João André Alves,3 Hayley D Germack,2 Timothy L Barnes,4 Meredith C McCormack5 1Respiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK;
Nordon C, Carstens D, Fagerås M, Müllerová H, Veeranki PS, Alves JA, Germack HD, Barnes TL, McCormack MC   +8 more
doaj  

Safety of GBL1204-An Ophthalmic Bevacizumab in Prefilled Syringe for Neovascular Age-Related Macular Degeneration: A Phase I Study. [PDF]

Ophthalmol Ther
Saraf A, Garima K, Dharwadkar S, Keshav S, Patwardhan SD, Giri NB, Saxena M, Phadke Y, Khare A, Mishra A, Kumar V, Singh S.   +11 more
europepmc   +1 more source

Evidence of the Utility of Needle-Free Injectable Devices for Subcutaneous Administration of Biopharmaceuticals: Comparable Study of in vivo Pharmacological and Vaccination Ability to Normal Injection. [PDF]

Med Devices (Auckl)
Taharabaru T, Kubohira Y, Taniguchi K, Horita T, Higashi T, Motoyama K.   +5 more
europepmc   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update. [PDF]

Cancer Med
Nath AD, Alam Y, Mim AM, Akter M, Gani MA, Alam KMK, Alam MN.   +6 more
europepmc   +1 more source

Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design. [PDF]

ESC Heart Fail
Quintana-Hayashi MP, Connolly K, Millegård M, Bhattacharya C, Åstrand M, Turton M, Pizzato PE, Januzzi JL, Rosenmeier JB.   +8 more
europepmc   +1 more source

A Novel Unadjuvanted Subunit Respiratory Syncytial Virus Prefusion F Vaccine Induces Potent and Differentiated Functional Immune Responses Compared to AS01-Adjuvanted Arexvy in Older Adults. [PDF]

Open Forum Infect Dis
Richmond P, Kwan TTL, Rook C, Sun A, Tan W, Jackson N, Ambrosino D, Siber G, Costa-Clemens SA, Clemens R, Burdin N, Liang JG.   +11 more
europepmc   +1 more source

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo

Scientific Reports, 2022
Maohua Li, Rongqing Zhao, Jianxin Chen, Wenzhi Tian, Chenxi Xia, Xudong Liu, Yingzi Li, Song Li, Hunter Sun, Tong Shen, Wenlin Ren, Le Sun   +11 more
doaj   +1 more source

Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countries. [PDF]

J Pharm Policy Pract
Fowler A, Tantri A, Spencer J, Grieve K, Pendharkar T, Da Silva Duarte Lepez S, Wilsdon T.   +6 more
europepmc   +1 more source